Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2022-05-26 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司章程
Governance Information Classification · 95% confidence The document is titled as the Articles of Association (章程) of 江苏浩欧博生物医药股份有限公司, dated May 2022. It contains detailed provisions about the company's organization, shareholder rights, board of directors, management, financial accounting, and other governance matters. The content is a comprehensive set of internal rules and regulations governing the company, including shareholder meetings, voting procedures, board responsibilities, and capital structure. There is no indication that this is an announcement, a financial report, or a voting result. It is a governance document outlining the company's internal rules and structure, which fits the definition of Governance Information (CGR). The document length is substantial and contains detailed governance content, not just a brief announcement or summary.
2022-05-26 Chinese
江苏浩欧博生物医药股份有限公司关于修改《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the amendment of the company's Articles of Association (公司章程). It details changes approved by the board and mentions that the amendments will be submitted to the shareholders' meeting for approval. There is no financial data, no mention of annual or interim reports, no audit information, no voting results, and no executive changes. The content is about governance structure changes, specifically the board composition and related company rules. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules and board structure changes.
2022-05-26 Chinese
江苏浩欧博生物医药股份有限公司关于召开2022年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about the convening of the 2022 second extraordinary general meeting of shareholders (临时股东大会) for Jiangsu Haobo Biopharmaceutical Co., Ltd. It includes information about the meeting date, voting methods (including cumulative voting), agenda items such as amendments to the company charter and election of directors, instructions for shareholders on voting and attendance, and attachments related to proxy authorization and voting procedures. There is no financial data or results reported, nor is it a transcript or presentation. It is not an announcement of voting results but a notice of the meeting itself. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2022-05-20 Chinese
江苏浩欧博生物医药股份有限公司独立董事关于公司第二届董事会第十七次会议相关事项的独立意见
Board/Management Information Classification · 100% confidence The document is an independent opinion from independent directors regarding the nomination and appointment of a new director and a new deputy general manager. It references compliance with company law, stock exchange listing rules, and company articles of association. The content focuses on board and senior management changes, specifically the appointment of a new director and deputy general manager. There is no financial data, earnings information, or report publication mentioned. The document length is short (1303 characters), and it is not an announcement of a report but a statement of board/management changes. Therefore, the appropriate classification is Board/Management Information (MANG).
2022-05-20 Chinese
江苏浩欧博生物医药股份有限公司关于增补公司董事及聘请副总经理的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Jiangsu Haoubo Biopharmaceutical Co., Ltd. regarding the addition of a new director and the appointment of a deputy general manager. It details the board meeting resolutions, qualifications of the appointee, and independent directors' opinions. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board and senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2022-05-20 Chinese
江苏浩欧博生物医药股份有限公司2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2021 Annual General Meeting Resolution Announcement" from Jiangsu Haobo Biomedical Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including approval of the 2021 annual report, board and supervisory reports, financial statements, profit distribution, and other corporate matters. The document includes voting percentages and confirms the legality and validity of the meeting and voting process. It does not contain the full annual report or financial statements themselves but reports the resolutions and voting outcomes from the AGM. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), which is the official results from shareholder votes at a general meeting. The document length is 4311 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, the correct classification is DVA.
2022-05-19 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.